HI homepage

John Simon, MD, CEO of SimonMed Imaging, said imaging had greatly advanced for noninvasive detection of disease and it may be time for imaging to play a greater role in annual physicals, and especially in executive physical exams.

John Simon, MD, CEO of SimonMed Imaging, says imaging has considerably advanced for noninvasive detection of disease and it may be time for it to play a greater role in annual physicals, especially in executive physical exams.
 

6-minute MRI can diagnose multiple sclerosis

The use of MRI and the “rule of 6” could significantly reduce the number of patients requiring lumbar punctures to diagnose the neurological condition.

ROB’E Robotic transesophageal echocardiography (TEE). ROB’E, a German startup, has developed a new remote-controlled robotic (RCR) system with these challenges in mind. Users are able to remotely manipulate TEE probes, performing precise movements and even saving specific positions so they can be duplicated as needed.

Researchers believe a new robotic TEE system could improve the long-term health of interventional echocardiographers in addition to several other key benefits.

Lung cancer screening stethoscope

Experts believe the model could improve risk stratification and offer patients more personalized screening strategies. 

Concussion brain

Imaging will play a prominent role in a new framework recently developed to better diagnose the severity of brain injuries. 

Video interview with Gregg Fonarow, MD, explaining the success of the AHA Get With The Guidelines-Stroke program, during AHA 2024.

Gregg Fonarow, MD, discussed the American Heart Association's stroke guidelines, the growing influence of AI and much more.

Around the web

RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model. 

 

Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.

A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.